Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Arch Dis Child Fetal Neonatal Ed ; 89(5): F412-6, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15321959

RESUMEN

OBJECTIVE: To determine the relation between lipid peroxidation and the antioxidants ascorbate, urate, and glutathione in epithelial lining fluid in ventilated premature babies, and to relate the biochemical findings to clinical outcome. DESIGN: A cohort study conducted between January 1999 and June 2001. SETTING: A NHS neonatal intensive care unit. PATIENTS: An opportunity sample of 43 ventilated babies of less than 32 weeks gestation. MAIN OUTCOME MEASURES: The duration of supplementary oxygen according to the definition of bronchopulmonary dysplasia (BPD; oxygen dependency at 36 weeks gestational age). METHODS: Epithelial lining fluid was sampled by bronchoalveolar lavage. Ascorbate, urate, glutathione, and malondialdehyde (a marker of lipid peroxidation) were measured. RESULTS: Babies who developed BPD had significantly lower initial glutathione concentrations (mean (SEM) 1.89 (0.62) v 10.76 (2.79) microM; p = 0.043) and higher malondialdehyde concentrations (mean (SEM) 1.3 (0.31) v 0.345 (0.09) microM; p < 0.05) in the epithelial lining fluid than those who were not oxygen dependent. These variables were poor predictors of the development of BPD. Gestational age, endotracheal infection, and septicaemia had good predictive power. The level of oxidative damage was associated with the presence of endotracheal infection/septicaemia rather than inspired oxygen concentration. CONCLUSIONS: Endotracheal infection, septicaemia, and gestational age, rather than antioxidant concentrations, are the most powerful predictors of the development of BPD.


Asunto(s)
Antioxidantes/metabolismo , Recien Nacido Prematuro/metabolismo , Pulmón/metabolismo , Estrés Oxidativo , Respiración Artificial , Envejecimiento/metabolismo , Ácido Ascórbico/metabolismo , Líquido del Lavado Bronquioalveolar/química , Displasia Broncopulmonar/metabolismo , Estudios de Cohortes , Glutatión/metabolismo , Humanos , Recién Nacido , Recien Nacido Prematuro/fisiología , Enfermedades del Prematuro/metabolismo , Infecciones/metabolismo , Peroxidación de Lípido , Modelos Logísticos , Malondialdehído/metabolismo , Oxígeno/administración & dosificación , Pronóstico , Ácido Úrico/metabolismo
2.
Early Hum Dev ; 30(3): 241-8, 1992 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-1468386

RESUMEN

Ninety-five premature newborns who had hyaline membrane disease and were struggling against the ventilator were randomised to one of three treatment groups: morphine (group M), pancuronium (group P) or morphine with pancuronium (group M+P). The dose of morphine was 50 micrograms/kg per h but was increased to 100 micrograms/kg per h in group M infants if they continued to struggle. The dosage of pancuronium was 100 micrograms/kg given as required to inhibit spontaneous respiration. Plasma catecholamine levels were measured on entry and at 24 h. Blood pressure and ventilatory requirements were determined on entry and at 6 h. The clinical outcome of the infants was documented. Group M infants (n = 29) showed a significant reduction in noradrenaline levels (median change -2.2 nmols/l (range -47.2 to +7.2 nmols/l), although seven were withdrawn from this group because of failure to settle. Group P (n = 28) and group M+P (n = 38) showed no significant change in noradrenaline levels. Comparison between the groups showed that group M infants had a significant reduction in noradrenaline levels compared with group P. The immediate effects of treatment on blood pressure and ventilatory requirements were similar in the three groups. The clinical outcome did not differ for any of the measured parameters. When adequate sedation is achieved, morphine may reduce the stress of newborn intensive care.


Asunto(s)
Enfermedad de la Membrana Hialina/terapia , Morfina/uso terapéutico , Pancuronio/uso terapéutico , Respiración Artificial , Estrés Fisiológico/prevención & control , Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Recién Nacido , Recien Nacido Prematuro , Morfina/administración & dosificación , Norepinefrina/sangre , Pancuronio/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA